Welcome to our dedicated page for Ctt Pharmaceutic SEC filings (Ticker: CTTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CTT Pharmaceutical Holdings, Inc. filings document the company’s registration-statement process and public-company disclosure framework. Its S-1/A record concerns a Securities Act registration statement for securities offered on a delayed or continuous basis and identifies CTT as a non-accelerated filer, smaller reporting company, and emerging growth company.
The filing record is tied to the company’s transition toward fully reporting status and covers offering structure, registrant information, reporting classifications, and formal SEC amendment activity for CTTH.
CTT Pharmaceutical Holdings, Inc. is registering 6,250,000 shares of common stock for resale by RH2 Equity Partners under an equity line of credit arrangement. These shares relate to an up to $10,000,000 equity line, where RH2 buys stock at 85% of the lowest 10-day VWAP, subject to a 4.99% beneficial ownership cap.
CTT will not receive proceeds from RH2’s resale of shares, but may receive cash when it sells stock to RH2 under the line. As of December 11, 2025, 58,712,232 shares were outstanding, and issuing all registered shares would raise this to 69,678,898. The company plans initially to use up to $1,000,000 from the facility, prioritizing about $500,000 for in‑house manufacturing equipment and paying roughly $2,000 per month for production space.
CTT is a development-stage drug delivery company focused on fast-dissolving oral strips for pharmaceuticals, nutraceuticals, nicotine and vitamins, with a history of losses and a going concern qualification. Management highlights significant regulatory, commercialization, dilution and penny stock risks, and notes that common stock traded at $0.0825 per share on the OTCQB on May 26, 2026.
CTT Pharmaceutical Holdings, Inc. has filed an amended Form S-1 to register up to 6,250,000 shares of common stock for resale by RH2 Equity Partners, the selling stockholder under an equity line of credit agreement. The company is not selling shares in this offering and will not receive proceeds from RH2’s resales, though it may raise up to $10,000,000 by selling shares directly to RH2 over a 24‑month period under the ELOC.
CTT focuses on fast‑dissolving oral drug delivery strips for pharmaceuticals, nutraceuticals and nicotine. It is a development-stage company with limited revenues, recent annual losses and a going concern qualification. The filing highlights significant regulatory, financing, dilution and penny‑stock risks, as well as dependence on future FDA processes for nicotine strips and on additional capital, including the equity line.